OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of adjuvant therapy with Dabrafenib ( Tafinlar ) plus Trametinib ( Mekinis ...


RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers ( NSCLCs ). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. ...


Among patients with non–small-cell lung cancer ( NSCLC ), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib ( Tabrecta ), a selective inhibitor of t ...


A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer ( NSCLC ). Researchers have evalua ...


Sintilimab ( Tyvyt ), an anti-PD-1 antibody, in combination with Pemetrexed and Platinum has shown promising activity for non-squamous non-small cell lung cancer ( nsqNSCLC ) in a phase 1b study. T ...


Ensartinib is a novel second-generation ALK tyrosine kinase inhibitor ( TKI ). In phase 1/2 studies, Ensartinib showed promising activity in patients with ALK+ non-small cell lung cancer ( NSCLC ) who ...


Malignant pleural mesothelioma ( MPM ) is a highly aggressive cancer; most patients are diagnosed with unresectable disease, and the 5-year survival rate is less than 10%. Standard of care treatmen ...


Nivolumab ( Opdivo ) + Ipilimumab ( Yervoy ) was shown to improve overall survival ( OS ) and durability of response versus chemotherapy in first line ( 1L ) advanced non-small cell lung cancer ( NSCL ...


KEYNOTE-177 is a phase 3, randomized open-label study evaluating the efficacy and safety of Pembrolizumab ( Keytruda ) versus standard of care chemotherapy ± Bevacizumab ( Avastin ) or Cetuximab ( Erb ...


Treatment with checkpoint inhibitors or targeted therapy improves outcomes in patients with BRAF V600–mutant advanced melanoma; however, many patients subsequently progress and die. Preliminary evide ...


Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men with nonmetastatic castration-resistant prostate cancer ( nmCR ...


In the phase 3 CheckMate 227 Part 1 ( minimum follow-up, 29.3 months ), first line 1L Nivolumab ( Opdivo ) + Ipilimumab ( Yervoy ) has significantly improved overall survival ( OS ) versus chemotherap ...


This is the first randomized trial testing the addition of an oncolytic virus to an immune checkpoint inhibitor for advanced melanoma. At the 3-year follow-up, the combination ( combo ) of Talimog ...


Selpercatinib ( Retevmo ) is a highly selective and potent small molecule RET kinase inhibitor. Researchers have reported an update on the efficacy and safety of Selpercatinib in RET-fusion+ non-smal ...


Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...